|Echo Therapeutics, Inc.|
99 Wood Avenue South
United States - Map
Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer market and diabetes outpatient market. It is developing Symphony continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system for use in hospital critical care units. The company is also developing Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses; and methotrexate-AzoneTS, a AzoneTS reformulation drug that has completed Phase II clinical studies for the treatment of early-stage mycoses fungoides, as well as developing for methotrexate-AzoneTS for the treatment of psoriasis. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.
|Mr. Scott W. Hollander ,
Chief Exec. Officer, Pres and Director
|Mr. Alan W. Schoenbart CPA,
Chief Financial Officer and Sec.
|Mr. Thomas H. Bishop ,
VP of Operations and Product Devel.
|Ms. Christine H. Olimpio ,
Director of Investor Relations & Corp. Communications
|Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|